Likes Subject
If one looks at the whole story, the Ecomike 08/31/22 4:57 PM
She went to one doctor, then another and another Giovanni 04/19/22 10:53 AM
Rubberneck doing dd :) Gatorca 05/27/23 2:28 PM
Some interesting listening..... https://twitter.com/KimDotcom/status/166169811 Rubberneck2 05/27/23 2:22 PM
Yeah like lemmings over the cliff. A rabbit JoeBenson 05/26/23 4:42 PM
No cliff here yet. Just in your own head. Nosnibor 05/26/23 2:55 PM
Sheep here Joe. They followed a pumper govprs 05/26/23 12:16 PM
Let me spell it out for you pal. You...are...not...getting...your...money...back JoeBenson 05/26/23 10:32 AM
China is bracing for a massive new wave Giovanni 05/24/23 10:16 AM
Thanks Gator I appreciate the info. Hotel Delta 05/23/23 7:24 PM
Solid buying for the day…nice.
Bullish
Bullish
threebabiesbusy 05/23/23 5:53 PM
Ah. That is where the risk factor comes Classic Warrior 05/23/23 1:26 PM
There is also a somewhat new face book Gatorca 05/23/23 9:43 AM
Gaps always fill…..I’m hoping however that we continue threebabiesbusy 05/22/23 9:55 PM
Evidently Rubberneck2 05/22/23 8:02 PM
I am not a scientist and neither is Classic Warrior 05/22/23 7:35 PM
Anyone with any sense and a little powder Rubberneck2 05/22/23 5:04 PM
Must be a leak, news pending, $$$$$$
Bullish
Bullish
Ecomike 05/22/23 3:16 PM
Because Buc works. bodyshop13 05/22/23 3:16 PM
OK, so why is it up over 25% longtrailer 05/22/23 3:01 PM
What are you waiting for? It's over. Stick JoeBenson 05/20/23 5:19 PM
Why continue to hope and pray? JoeBenson 05/20/23 5:13 PM
Gov I not angry at anyone. And I have Naught 05/19/23 8:33 PM
would have been nice to have them meet alabama1man 05/18/23 8:39 AM
Yes it matters and yes Bucillamine should do Hattrick3 05/17/23 10:20 PM
Hey There Medicinecat, Hattrick3 05/17/23 10:15 PM
This is not true. As Rick, pointed out Classic Warrior 05/17/23 5:06 PM
Good afternoon Hattrick. Good to hear from you medicinecat 05/17/23 4:28 PM
The new COVID variant has symptoms that are Giovanni 05/17/23 10:49 AM
Good Morning Mike Giovanni 05/17/23 9:46 AM
Does restoration of glutathione matter? Giovanni 05/17/23 9:24 AM
No Bard is a LLM and doesn't have access mrfumbles 05/17/23 9:18 AM
Is this true? Hotel Delta 05/17/23 8:46 AM
Hattrick3 Nice and concise. Now we wait. Naught 05/16/23 11:12 PM
Ditto. threebabiesbusy 05/16/23 10:30 AM
Im assuming nobody. No point in selling at tripmcneely 05/16/23 8:35 AM
So how many of you sold shares? I've
Bullish
Bullish
Hotel Delta 05/16/23 7:26 AM
Hey Gatorca, Giovanni, Warrior. I need two gin JoeBenson 05/13/23 3:10 PM
Repost.................. Another day, another semi-meltdown from some holders rickstereo3333 05/13/23 3:08 PM
Yep that’s the facts. Everything else is govprs 05/13/23 9:53 AM
Eco Kudos for some semblance of reality here. Let Naught 05/13/23 9:25 AM
Eco Kudos for some semblance of reality here. Let
Bullish
Bullish
Naught 05/13/23 9:21 AM
To be clear..... (PR excerpt): PennyWorld 05/13/23 6:35 AM
Good evening sir. I see reading comprehension, is
Bullish
Bullish
Ecomike 05/12/23 11:36 PM
Thanks. That makes sense. Back to the FDA Classic Warrior 05/12/23 9:07 PM
When a company meets with the DSMB on Hattrick3 05/12/23 6:21 PM
Better to hold for 10 years than sell Rubberneck2 05/12/23 5:45 PM
about the only good thing I see here alabama1man 05/12/23 5:37 PM
I hear you Gator. I still would have Classic Warrior 05/12/23 3:12 PM
https://twitter.com/revivethera/status/1657061031036993537?t=s3WntUetjoEcejcuVxVz8w&s=19 Ps. Gatorca 05/12/23 2:08 PM
Patronizing little peasant aren't you? You misinterpreted my Nosnibor 05/12/23 1:34 PM
R.I.P. Revive ReviveThomas 05/12/23 1:27 PM
Likes Subject

Ecomike
08/31/22 4:57 PM
Gatorca
05/27/23 2:28 PM
JoeBenson
05/26/23 4:42 PM
Nosnibor
05/26/23 2:55 PM
govprs
05/26/23 12:16 PM
Giovanni
05/24/23 10:16 AM
Hotel Delta
05/23/23 7:24 PM
threebabiesbusy
05/23/23 5:53 PM
Classic Warrior
05/23/23 1:26 PM
Gatorca
05/23/23 9:43 AM
Rubberneck2
05/22/23 8:02 PM
Classic Warrior
05/22/23 7:35 PM
Rubberneck2
05/22/23 5:04 PM
Ecomike
05/22/23 3:16 PM
bodyshop13
05/22/23 3:16 PM
longtrailer
05/22/23 3:01 PM
JoeBenson
05/20/23 5:19 PM
JoeBenson
05/20/23 5:13 PM
Naught
05/19/23 8:33 PM
alabama1man
05/18/23 8:39 AM
Hattrick3
05/17/23 10:20 PM
Hattrick3
05/17/23 10:15 PM
Classic Warrior
05/17/23 5:06 PM
medicinecat
05/17/23 4:28 PM
Giovanni
05/17/23 10:49 AM
Giovanni
05/17/23 9:46 AM
Giovanni
05/17/23 9:24 AM
mrfumbles
05/17/23 9:18 AM
Hotel Delta
05/17/23 8:46 AM
Naught
05/16/23 11:12 PM
threebabiesbusy
05/16/23 10:30 AM
tripmcneely
05/16/23 8:35 AM
Hotel Delta
05/16/23 7:26 AM
PennyWorld
05/13/23 6:35 AM
Classic Warrior
05/12/23 9:07 PM
Hattrick3
05/12/23 6:21 PM
Rubberneck2
05/12/23 5:45 PM
alabama1man
05/12/23 5:37 PM
Classic Warrior
05/12/23 3:12 PM
ReviveThomas
05/12/23 1:27 PM

Revive Therapeutics Ltd (RVVTF)

Followers
348
Posters
635
Posts (Today)
0
Posts (Total)
35766
Created
02/23/17
Type
Free
Moderators PennyWorld Ecomike Weedman1 Classic Warrior
revive-therapeutics.png

drug
 

Revive Therapeutics updates on potential COVID-19 treatment, and its oral form of Psilosybin 

 

Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases.

https://www.globenewswire.com/news-release/2020/04/08/2013654/0/en/Revive-Therapeutics-Engages-Novotech-as-Asia-Pacific-CRO-for-Bucillamine-in-the-Treatment-of-Infectious-Diseases.html



Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19
 

FDA’s support in advising Revive to move directly into a Phase 3 confirmatory trial provides an acknowledgment for the potential of Bucillamine in the treatment of COVID-19,” said Michael Frank, Chief Executive Officer of Revive. "Entering into a Phase 3 study is a major milestone for the Company, and we are excited to unlock the full potential of Bucillamine not only for this virus but also for other infectious diseases that we will investigate in the future.”

In addition to its recommendation, the FDA provided valuable guidance on study design and outcome measures for the Phase 3 study.  Importantly, the FDA agreed that Revive could rely on its data included in its previous IND with Bucillamine for gout to support the COVID-19 Phase 3 study and, therefore, the Company did not have to perform any Phase 1 or Phase 2 clinical studies.  The Company, along with its Contract Research Organization, Pharm-Olam, LLC, and its clinical development team led by Dr. Kelly McKee, Jr., MD, MPH, Chief Scientific Officer consultant and Dr. Onesmo Mpanju, PhD, Regulatory Affairs consultant, are actively incorporating the pre-IND meeting guidance and preparing the package for submission to the FDA.  The Company expects to file the final IND within the next 60 days and will plan to initiate the Phase 3 study thereafter.

Scientific Rationale of Bucillamine

Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs and to help treat COVID-19 manifestations.

Bucillamine-induced Pneumonitis in a Patient With Rheumatoid Arthritis-associated Interstitial Pneumonia: A Case Report and Review of the Literature
An 81-year-old woman with rheumatoid arthritis (RA) who had been treated with bucillamine presented with dyspnea. Computed tomography of the chest showed ground-glass opacities and consolidations in both lungs and honeycombing in both basal lung areas. An elevation of the serum Krebs von den Lungen-6 level and hypoxemia were seen. Lymphocytosis with a decreased CD4/CD8 ratio was seen in the bronchoalveolar lavage fluid. A transbronchial lung biopsy specimen showed organizing pneumonia. Based on a diagnosis of bucillamine-induced pneumonitis (BIP) with RA-associated pre-existing interstitial pneumonia, she was successfully treated with the cessation of bucillamine and systemic corticosteroid therapy. The risk factors and prognosis of BIP are discussed.

https://pubmed.ncbi.nlm.nih.gov/30918198/

 






CEO Interview: May 2020
https://www.youtube.com/watch?v=mOoawz-iK-M






May 2020 Revive Therapuetics Company Presentation https://www.revivethera.com/uploads/1/0/1/0/101019330/rvv_deck_-_may2020v3.pdf

 Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (Phase 3.)
 Developing novel Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders. 
 Robust patent portfolio covering methods and compositions of drugs. 
 Significantly undervalued compared to its peers.






PATENT PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Issued on May 30, 2017 Drug Delivery System US 8642088 US 9545423 US 10104888 Issued on February 4, 2014 Issued on January 17, 2017 Issued on October 23, 2018 Psilocybin effervescent and psilocybin tablet - Solid Oral Pharmaceutical Compositions 62/985,052 Provisional patent filed Psilocybin hard-shell capsules - Pharmaceutical Capsule Compositions 62/985,070 Provisional patent filed Psilocybin gum drops - Pharmaceutical Gumdrop Compositions 62/985,084 Provisional patent filed Psilocybin oral strips and transmucosal - Thin-Film Pharmaceutical Delivery System and Formulations 62/985,098 Provisional patent filed Psilocybin - Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration 62/984,590 Provisional patent filed Methods for the Extraction and Crystallization of Psilocybin 62/985,360 Provisional patent filed Use of Cannabidiol in the Treatment of Autoimmune Hepatitis US 8242178 Issued on August 14, 2012

Focus on Infectious Diseases, including COVID-19, and Rare Disorders:

1. Bucillamine Infectious Diseases (COVID-19) Filing IND IND for Phase 3 Market size =TBD 
2. Psilocybin Undisclosed Pre-clinical Target FDA Orphan Status + $500M
3. Psilocybin Undisclosed Multiple Indications Pre-clinical Target FDA Orphan Status Market size =TBD
4. CBD Liver Diseases (Autoimmune Hepatitis) Filing IND Received FDA Orphan Status IND for Phase 2 Psilocybin Undisclosed Pre-clinical Target FDA Orphan Status + $500M Psilocybin Undisclosed Multiple Indications Pre-clinical Target FDA Orphan Status TBD + $100M 50k US Population

Infectious Disease Opportunity:

Focus on Bucillamine in the treatment of infectious diseases § Well-known safety profile and prescribed for arthritis in Japan and South Korea for over 30 years §
Revive’s clinical history with Bucillamine § Obtained 2 FDA INDs with Bucillamine and FDA orphan drug status § FDA Phase 2 clinical study for acute gout flares and cystinuria § Bucillamine (BUC) scientific rationale as an intervention for COVID-19 (see Appendix) § BUC is 16x more potent than particularly N-acetylcysteine (NAC); NAC has shown to prevent acute lung injury caused by influenza virus                                                                                                                   BUC shown superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection
 BUC also shown to prevent oxidative and reperfusion injury in heart and liver tissues §
 BUC proven safety and MOA similar to NAC, but with much higher potency §
Advancing towards FDA Phase 3 clinical study for COVID-19

Pschedelic Opportunity 

§ Acquired Psilocin Pharma Corp. § Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis § Worked with Xanthic Bio Pharma and Green Growth Brands
§ Developed water Soluble THC and CBD products (Beverages, effervescent tablets)
§ Novel Psilocybin formulations, extraction and purification methods
§ Suited for pharmaceutical development and recreational markets where legal
§ Patent pending Psilocybin formulations (natural synthetic derived)
§ Capsules, Sublingual Spray, Gel Cap, Effervescent Tablets, and Oral Strips
§ Targeting rare diseases, mental health and addiction


LIVER DISEASE OPPORTUNITY
§ Focus on Autoimmune Hepatitis (AIH) § AIH - rare disease (~ 76k patients in US) causing liver inflammation • Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug withdrawal in 50%-86%*
§ Obtained FDA orphan drug status for CBD in the treatment of AIH
§ Seeking to file FDA IND to conduct Phase 2 clinical study in patient affected by AIH § Big Pharma interest in liver diseases § Allergan acquisition of Tobira for $1.7 billion
§ Novartis license of Conatus drug for $650 million
§ Gilead acquisition of Nimbus for $1.2 billion


STRATEGIC PARTNERS:
A. Pharm Olam
B.Psilocin Corp (Aquired) 
C.Wisconsin University
D.South Carolina University 
E.WARF Wisconsin Alumni Research Foundation 
F.Sanyal Biotechnology 

Value Driving Milestones for 2020
Q2 Submit FDA IND for Phase 3 clinical study of Bucillamine in the treatment of COVID-19
Q2 Initiate Phase 3 clinical study of Bucillamine in the treatment of COVID-19 in the U.S.
Q2 
Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q2/3 Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
Q3 Initiate Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q3 Pre-IND meeting with FDA for Psilocybin (undisclosed indications)
Q3/4 Results from Phase 3 clinical study of Bucillamine in the treatment of COVID-19
Q4 Results from Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)

Team:

Management § Michael Frank Chairman and CEO § Carmelo Marrelli Chief Financial Officer § Derrick Welsh Founder, Psilocin Pharma Corp. Clinical § Dr. Kelly McKee, Jr., MD, MPH Chief Scientific Officer, Consultant § Dr. David Boulware, MD, MPH, CTropMed, FIDSA Clinical and Scientific Advisor § Dr. Onesmo Mpanju, PhD FDA Regulatory Affairs, Consultant. Board of Directors § Michael Frank Chairman and CEO § William Jackson Director § Joshua Herman Director § Christian Scovenna Director § Andrew Lindzon Director.


Appendix – Bucillamine Scientific Rationale for COVID-19

Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficacy when not delivered early.1 This is because these drugs mostly act to prevent the early processes of virus binding to cells or viral replication.2 Thiols, particularly N-acetylcysteine (NAC), with antioxidant and reducing activity have been investigated as effective therapies that abrogate the potential for influenza to cause severe disease.3,4,5 Restoration of glutathione, the major intracellular thiol antioxidant, is a critical functional activity of NAC.6 Reactive oxygen species (ROS) generation during influenza virus infection aggravate destructive inflammation and programmed death of epithelial cells.7 Studies in human cells and animal models have shown that NAC works to prevent acute lung injury caused by influenza virus infection through inhibition of these ROS-mediated mechanisms.4,7 NAC has been investigated clinically and found to significantly attenuate clinical symptoms associated with influenza infection, especially in elderly at-risk patients.5 While NAC is easily taken up by cells and has low toxicity, clinical efficacy has required long-term and high-dose administration because of modest relative potency, limiting its clinical applicability. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.8 Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of Bucillamine as an intervention for COVID-19.

ying the investigation of Bucillamine as an intervention for COVID-19. Appendix – Bucillamine Scientific Rationale for COVID-19

s 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. 2. Duwe S. Influenza viruses – antiviral therapy and resistance. GMS Infect Dis. 2017; 5: Doc04. 3. Zhang RH, Li CH, Wang CL et al. N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury. Int Immunopharmacol. 2014 Sep;22(1):1-8. doi: 10.1016/j.intimp.2014.06.013. 4. Ungheri D, Pisani C, Sanson G et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol. 2000 SepDec;13(3):123-128. 5. De Flora S, Grassi C, and Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535–1541 DOI: 10.1183/09031936.97.10071535 6. Poole LB. The Basics of Thiols and Cysteines in Redox Biology and Chemistry. Free Radic Biol Med. 2015 Mar; 0: 148–157. doi: 10.1016/j.freeradbiomed.2014.11.013. 7. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011 Sep 1;82(5):548-55. doi: 10.1016/j.bcp.2011.05.014. 8. Horowitz LD. Bucillamine: a potent thiol donor with multiple clinical applications. Cardiovasc Drug Rev. 2003 Summer;21(2):77-90. 9. Sagawa A, Fujisaku A, Ohnishi K et al. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study). Mod Rheumatol. 2011 Jun;21(3):251-7. doi: 10.1007/s10165-010-0385-4

https://www.globenewswire.com/news-release/2020/04/23/2020948/0/en/Revive-Therapeutics-Announces-U-S-FDA-Recommendation-to-Proceed-Directly-Into-A-Phase-3-Confirmatory-Clinical-Trial.html

https://www.globenewswire.com/news-release/2020/03/25/2006595/0/en/Revive-Therapeutics-Engages-Pharma-Olam-and-Strengthens-Infectious-Diseases-Clinical-Development-Team-to-Advance-U-S-FDA-Clinical-Study-for-COVID-19.html

https://www.thecannabisinvestor.ca/3-psychedelic-stocks-investors-should-have-on-their-radar-in-2020/

https://www.globenewswire.com/news-release/2020/04/29/2024191/0/en/Revive-Therapeutics-Provides-an-Update-on-its-Psilocybin-Based-Pharmaceutical-Program.html

https://www.globenewswire.com/news-release/2020/03/05/1996118/0/en/Revive-Announces-Closing-of-the-Acquisition-of-Psilocin-Pharma-Corp.html

Websitehttps://www.revivethera.com




Picture


Advancing Psilocybin Drug Development.

 

About Psilocin Pharma Corp.

 
Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions.
 
 

 

Latest Press Releases

 
17/04/2020
Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals

17/04/2020
Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

?18/03/2020
Revive Announces Announces Closing of Brokered Private Placement

05/03/2020

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.
?

05/03/2020

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

12/02/2020 - 
Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.


Our Products

 

We have developed six unique formulations to date in the form of Capsules (PSY-0.1),  Sublingual Spray (PSY-0.2), Gel Cap (PSY-0.3), Effervesce Tablets (PSY-0.4/0.5), Breath Strip (PSY-0.6). The precisely dosed formulations work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to eventually FDA approval in the treatment of Depression, Anxiety, Bi-polar disorder, Bulimia & Anorexia Nervosa, etc.  Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. 
 

Market Opportunity (MEDICAL)

 

Mental Health (Depression, PTSD & Anxiety)
  • 450,000,000 people globally suffer from mental health illness
Eating Disorders (Anorexia, Bulimia & other classified EDs)
  •  70,000,000 people globally suffer from an eating disorder
Addiction (Alcohol, Drugs, Cigarettes)
  • 240,000,000 people globally suffer from addiction 

Market Opportunity (NUTRACEUTICAL)

 

Supplements for Brain Health & Cognitive Enhancement
  • Millions of people around the world are taking some form of   supplement (B12, B9, Omega 3, Vitamin D, Gingko Biloba and   others (4)) for brain health and/or cognitive enhancement   reasons
Global Market
  •  Global market size for these types of brain enhancing   supplements can reach $5.8 Billion US by 2023 (5)
 

Product Pipeline

 

Hard-shelled Capsules 

?Product highlights:
  • Contain dry, powdered ingredients or miniature pellets made by e.g. processes of Extrusion or Spherization
    Often easier to swallow
    Protects sensitive ingredients
    Easily opened
    Reduced stomach irritation
    Unique ingredient combinations are possible
    Gelatin and vegetarian enclosure options
    Oil or fat-soluble nutrient delivery options
 

 
Oral Sprays

?Advantages: 
  • Sublingual spray give faster onset and longer duration of action. It provides ease of administration to patients who refuse to swallow a tablet.
    There is no requirement of drug disintegration.
    Patients who experience dry mouth, the spray can be a better alternative, since the dissolution of the spray is not dependent upon patient’s saliva.
    Elimination of first pass metabolism, good mouth feels property.
    Low dosage provides high efficacy as hepatic first pass metabolism is avoided and also reduces the risk of side effects.
 

 
Gel Caps
?
?Product Highlights:
  • Often easier to swallow
    Protects sensitive ingredients
    Easily opened
    Reduced stomach irritation
    Unique ingredient combinations are possible
    Gelatin and vegetarian enclosure options
    Oil or fat-soluble nutrient delivery options
 

 
Effervescents

Psilocybin has quality’s that could be uniquely paired with Effervescent formulations:
  • Increased uptake of Psilocin
    Rapid metabolization via sublingual absorption path way
    Easily dosed and titrated
    Easily packaged and produced
    Gentile on the gastrointestinal track
    Marketing advantages   
 

 
Oral Fast Dissolving Film
?
  • Proprietary oral fast-dissolving drug delivery system, fast psilocin, rapidly releases an expansive list of pharmaceuticals, emulsified psilocybin
    ?
    This permits API’s to enter the blood stream through a fast dose pathway without being degraded or modified by first pass metabolism in the liver.
     
    Sublingual and transmucosal transport of active molecules result from the rapid dissolution of Fast Strips combined with the proprietary technolo
     
Picture
 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
RVVTF Latest News
  • No Recent News Available for this company!
New Post